References
- Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med.363(9), 809–819 (2010).
- Bollag G, Hirth P, Tsai J et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature467(7315), 596–599 (2010).
- Solit DB, Garraway LA, Pratilas CA et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature439, 358–362 (2006).
- Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature468(7326), 968–972 (2010).
- Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature468(7326), 973–977 (2010).
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60(5), 277–300(2010).
- Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N. Engl. J. Med.351, 998–1012 (2004).
- Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17, 2105–2116 (1999).
- Bedikian AY, Millward M, Pehamberger H et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol.24, 4738–4745 (2006).
- Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature417, 949–954 (2002).
- Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res.70(13), 5518–5527 (2010).
- Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.362, 2260–2270 (2010).
- Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.362, 2251–2259 (2010).
- Solit D, Sawyers CL. Drug discovery: how melanomas bypass new therapy. Nature468(7326), 902–903 (2010).
- Ledford H. The roots of resistance. Nature468, 490 (2010).
- Heard E, Tishkoff S, Todd JA et al. Ten years of genetics and genomics: what have we achieved and where are we heading? Nat. Rev. Genet.11(10), 723–733 (2010).
- Gerstein MB, Lu ZJ, Van Nostrand EL et al. Integrative analysis of the Caenorhabditis elegans genome by the modENCODE Project. Science330(6012), 1775–1787 (2010).
- Roy S, Ernst J, Kharchenko PV et al.; modENCODE Consortium. Identification of functional elements and regulatory circuits by Drosophila modENCODE. Science330(6012), 1787–1797 (2010).
- Beltrao P, Cagney G, Krogan N. Quantitative genetic interactions reveal biological modularity. Cell141(5), 739–745 (2010).
- Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov.9(10), 775–789 (2010).
- Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol.28(10), 1069–1078 (2010).